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Abstract
Merkel Cell Carcinoma (MCC) is a rare and highly aggressive neuroendocrine skin cancer for which no effective treatment is
available. MCC represents a human cancer with the best experimental evidence for a causal role of a polyoma virus. Large T
antigens (LTA) encoded by polyoma viruses are oncoproteins, which are thought to require support of cellular heat shock
protein 70 (HSP70) to exert their transforming activity. Here we evaluated the capability of MAL3-101, a synthetic HSP70
inhibitor, to limit proliferation and survival of various MCC cell lines. Remarkably, MAL3-101 treatment resulted in
considerable apoptosis in 5 out of 7 MCC cell lines. While this effect was not associated with the viral status of the MCC cells,
quantitative mRNA expression analysis of the known HSP70 isoforms revealed a significant correlation between MAL3-101
sensitivity and HSC70 expression, the most prominent isoform in all cell lines. Moreover, MAL3-101 also exhibited in vivo
antitumor activity in an MCC xenograft model suggesting that this substance or related compounds are potential
therapeutics for the treatment of MCC in the future.
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Introduction
Merkel Cell Carcinoma (MCC) is a highly aggressive neuroen-
docrine skin cancer, which primarily affects elderly or immuno-
compromised individuals [1,2]. MCC is a rare disease, but its
incidence is rapidly increasing [3,4]. Treatment of primary tumors
includes surgical resection and adjuvant radiotherapy [5,6].
Therapeutic options for advanced disease are of limited efficacy
with no proven benefit on overall survival [7–11]. MCC is
associated in the majority of cases with Merkel cell polyoma virus
(MCPyV). Indeed, MCC represents the human cancer with the
best experimental evidence for a causal role of a polyoma virus,
and expression of the T antigens by MCPyV is required for growth
of MCC cells in cell culture and in xenografts [12,13]. In
particular, MCC cells depend on large T antigen (LTA) and its
ability to interact with Retinoblastoma protein (Rb) [12]. It is
believed that this interaction requires the activity of a cellular heat
shock protein 70, or HSP70 [14].
Members of the HSP70 superfamily are highly expressed in
many cancers [15,16]. Notably, high HSP70 expression is
associated with poor prognosis and resistance to chemotherapy
while low HSP70 levels correlate with reduced tumorigenicity
[15,17]. The HSP70 superfamily is evolutionary highly conserved
and consists of 17 isoforms [18]. Besides stress-inducible variants
the family also includes the constitutively expressed HSC70
(HSPA8) [19]. HSP70 proteins are ATP-dependent molecular
chaperones that regulate diverse cellular functions, including
folding and assembly of newly synthesized as well as refolding of
misfolded proteins, transport of proteins across intracellular
membranes and maintenance of protein homeostasis within the
cell [20]. Moreover, HSPs can interfere with cell death at different
stages by blocking apoptosis in a caspase-dependent or indepen-
dent manner [15,21]. While the precise mechanisms by which
HSP70 exerts its anti-apoptotic function are not yet fully
understood, inactivation of HSP70 may hold great therapeutic
value as HSP70-inactivating antisense oligonucleotides efficiently
triggered cell death and cell cycle arrest in cancer cells [19,22,23].
MAL3-101 is a small molecule HSP70 inhibitor and exerts anti-
proliferative and pro-apoptotic effects on cell lines derived from
various cancers, including small cell lung carcinoma [24,25].
MAL3-101 is a membrane permeable dihydropyrimidine analog
that modulates the ATPase activity of HSP70 proteins and, in
particular, inhibits the ATPase activity induced by simian virus 40
LTA, which interacts with HSP70 proteins via its J-domain [26].
LTAs promote G1/S cell cycle progression by inactivating
proteins from the Rb family [27–29]. Notably, both the J-domain
of LTA and HSC70-dependent ATP hydrolysis is required for Rb
inactivation [30–32].
Although it has not yet been established whether binding of
HSC70 by MCPyV LTA is required to support proliferation of
MCC cells, it has been demonstrated that MCPyV LTA binds
HSC70 via the J-domain, and that this interaction facilitates
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MCPyV replication [14]. As HSP70 proteins generally support
growth and survival of tumor cells and may be particularly critical
for MCPyV-transformed MCC cells, we evaluated the impact of
MAL3-101 on MCC cell lines. These experiments revealed
apoptosis induction in vitro as well as significant MCC tumor
inhibition in vivo in a xenograft murine model. Strikingly, the
efficiency of MAL3-101 correlated with HSC70 expression, but
did not require the presence of MCPyV LTA in the analyzed cells.
Material and Methods
Ethics statement
The presented work was conducted according to the principles
expressed in the Declaration of Helsinki. The generation and
characterization of MCC cell lines was approved by the
Institutional Review Board of University Hospital Wu¨rzburg
(sequential study number 124/05). All the animal experiments
were approved by the local authorities (government of Unter-
franken; animal experiment request AZ: 55.2-2531.01-59/06)
according to the legal requirements.
Cell lines, cultures and reagents
The human MCPyV+ cell lines WaGa, BroLi, MKL-1 and
MKL-2 as well as the MCPyV- MCC cell lines UISO, MCC13
and MCC26 have been described previously [13,33–35]. In
addition, this cell panel was complemented by the melanoma cell
line FM88 [36], the T-cell line Jurkat [37] and HaCat
keratinocytes [38], primary human keratinocytes and primary
human fibroblasts. Primary human keratinocytes were obtained
from foreskin and cultured as described [39]. Primary human
fibroblasts were isolated from skin biopsies as described by Green
et. al [40]. Recently, it was suggested that UISO might be not
representative of Merkel cell carcinoma [41].
All MCC cell lines, as well as the FM88 and Jurkat line were
grown in RPMI1640 (PAN Biotech, Aidenbach, Germany)
supplemented with 10% (v/v) FCS (Biochrom AG, Berlin,
Germany), 100 U/ml penicillin, and 100 mg/ml streptomycin
(Sigma Aldrich, Munich, Germany), and maintained in a
humidified atmosphere with 5% (v/v) CO2.
Trypan-blue exclusion assay
Cell proliferation and viability under MAL3-101 treatment was
measured using the trypan blue exclusion assay. After treatment,
the cells from each group were stained with 0.4% trypan blue
(Sigma Aldrich GmbH) and the number of dye-excluding (living)
cells and positively blue stained (dead) cells was counted using a
haemocytometer.
Annexin V assay and cell cycle analysis
Apoptosis analysis was performed using the PE Annexin-V
Apoptosis Detection Kit (BD Biosciences, Heidelberg, Germany)
according to the manufacturer’s instructions. Early apoptotic cells
are identified as Annexin-V-positive and 7-AAD-negative, while
late apoptotic cells are positive for both.
For cell cycle analysis, DNA staining was performed following
overnight fixation with ethanol (90%). Cells were then pelleted and
resuspended in PBS supplemented with 1% FCS, 0.05 mg/ml
propidium iodide (Sigma Aldrich GmbH), and 0.1 mg/ml RNase
A (Fermentas GmbH, St. Leon-Rot, Germany). After a one hour
incubation at 37uC, cells were measured on a FACSCanto flow
cytometer (BD Biosciences). Data were evaluated using FlowJo
analysis software (Tree Star, Inc., Ashland, OR, USA).
Real time polymerase chain reaction (PCR) for HSP70
isoforms
Relative expression levels of the HSP70 isoforms were
determined by SybrGreen real time PCR applying the compar-
ative DD2CT method. Total cellular RNA was isolated using the
RNAeasy kit (Qiagen, Hilden, Germany) with a subsequent
DNaseI digestion step according to the manufacturer’s instructions
followed by cDNA synthesis with the Superscript II RT First
Strand Kit (Invitrogen GmbH, Karlsruhe).
Real time PCR was conducted in the ABI 7500 Fast Real-Time
PCR cycler (Applied Biosystems Inc., Foster City, CA, USA). The
standard PCR reactions (20 ml) contained 1 ml cDNA and 10 ml
26 SybrGreen I Low Rox Mastermix (Eurogentec GmbH,
Cologne, Germany) for detection. The thermal cycling conditions
comprised an initial denaturation step at 95 uC for 10 min,
followed by 40 cycles of three-step PCR including 15 sec at 95 uC,
60 sec at 60 uC and 30 sec at 95 uC. The CT levels of the investigated
HSP70 isoforms were normalized to GAPDH (D-CT level). D-CT
was calculated as CT HSP isoform, sample - CT GAPDH, sample.
Primer pairs for the different HSP70 isoforms were selected
from NCI qPrimerDepot (Table 1) (http://primerdepot.nci.nih.
gov/).
Xenograft model, tumor induction and treatment
protocols
Female NOD.CB17/JHliHsd-Prkdcscid mice were purchased
from Harlan Laboratories GmbH (Eystrup, Germany) at the age
of 4-6 weeks. All mice were housed under specific pathogen-free
conditions according to the animal care guidelines in the
Department of Dermatology of the University Hospital Wu¨rzburg
(Germany).
Tumors were established by injection of 56106 WaGa cells
(mixed 1:2 with MatriGel, BD Biosciences) in a final volume of
100 ml subcutaneously into the lateral flank. The volume of the
tumors was determined by measuring the diameter in two
dimensions with a slide gauche and applying the following
formula: V= p/6 6 a2 6 b (a: length; b: width) twice weekly.
When the tumors reached a volume of approximately 100 mm3,
the mice were randomly divided into two groups (n = 6): i.e., the
vehicle control group (mice injected intraperitoneally with 200 ml
of PBS/20%DMSO every second day) and the MAL3-101 group
(mice injected intraperitoneally with 40 mg/kg MAL3-101 every
other day). The mice were closely monitored. On day 38, the
experiment was terminated due to tumor size in the control group.
Immunohistochemistry (IHC)
To measure the levels of HSP70 expression in vitro and in vivo,
either cultured cells embedded in a bovine plasma/thrombin (5:1)
clot prior to formalin fixation, archived formalin-fixed and
paraffin-embedded (FFPE) tumor samples from MCC patients,
or FFPE samples from xenografted tumors were used. Antigen
retrieval was achieved by incubation of the de-paraffinized sections
with Dako Target Retrieval Solution (Dako, Hamburg, Germany),
pH 6.0. For inactivation of endogenous peroxidases, slides were
incubated with peroxidase blocking solution (Dako, Hamburg,
Germany). Subsequently, sections were incubated overnight with
the primary antibody (HSPA4/8, 1:100, mouse monoclonal
antibody, clon N27F3-4, Abnova GmbH, Heidelberg, Germany;
Cleaved Caspase-3 (Asp175), 1:1000, rabbit monoclonal antibody,
Cell Signaling Technology, Inc., Danvers, MA, USA) in a
humidified chamber at 4uC. For detection, the EnVision system-
polymer HRP-labelled anti-rabbit or anti-mouse secondary
antibodies (Dako) were applied followed by incubation with the
HSP70 Inhibition and Merkel Cell Carcinoma
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Nova Red substrate kit (Linearis, Wertheim, Germany) according
to the manufacturer’s protocol. Finally, slides were counterstained
with Mayer’s hematoxylin (Dako).
Statistical analysis
All quantitative assays were performed in triplicate. To evaluate
the correlation between HSC70 expression levels and MAL3-101
sensitivity, relative gene expression levels were compared with the
percentage of living cells after MAL3-101 treatment. Gaussian
distribution of the data was confirmed by using the Shapiro-Wilk
normality test. The correlation was determined using Spearman’s
correlation coefficient. Tumor volumes are expressed as means
+/2 SD. The related 2-way ANOVA was performed to determine
significance of differences in tumor volume between vehicle and
MAL3-101 treated animals. The statistical analysis was performed
with GraphPad Prism 5.03 software (GraphPad Software, Inc. La
Jolla, CA, USA). A value of p , 0.05 was considered significant.
Table 1. Primer pairs for HSP70 isoform quantification by real-time PCR.
primer sequence
HSP70 isoform Forward Reverse
HSPA1B 5‘-TGAAGCAGCAAAGAGCTGAA-3‘ 5‘-GTGGATTAGGGGCCTTTGTT-3‘
HSPA2 5‘-AAAGTTTGCTGATGATGGGG-3‘ 5‘-TCGACAAGTGTCAGGAGGTG-3‘
HSPA4 5‘-TACCTGGCTTTTAGCTGCTG-3‘ 5‘-CGCTAATGAGTATAGCGACCG-3‘
HSPA5 5‘-TGATTGTCTTTTGTCAGGGGT-3‘ 5‘-CACAGTGGTGCCTACCAAGA-3‘
HSPA6 5‘-GATAAGTCAGCTGTGACTGTCAGG-3‘ 5‘-TTATTTGAAGCAGAAGAGGATGAA-3‘
HSPA7 5‘-TTCCATGAAGTGGTTCACGA-3‘ 5‘-TTGACGCTGGTGTCTTTGAG-3‘
HSPA8 5‘-TGGAAAACACCCACACAAGA-3‘ 5‘-TCCTTCGTTATTGGAGCCAG-3‘
HSPA9B 5‘-ATTGAGCACGGGTCAACTTC-3‘ 5‘-ATGGCACTTCAGAGGGTACG-3‘
HSPA12A 5‘-CAGGAATAACGCCTCTGTCC-3‘ 5‘-CACCACGAGAAATGACTGCT-3‘
HSPA14 5‘-ATTCGAGAAGACCCTCCACA-3‘ 5‘-GCAATGTGTCCAGAGCAAGA-3‘
APG-1 5‘-CATTTCCAATGGCTCGAGTT-3‘ 5‘-CATTGCTGTCGCGAGAAGT-3‘
STCH 5‘-GAGCCAACATATTCTGGGGA-3‘ 5‘-GGCTGAAATTGGCAGATACC-3‘
HSPH1 5‘-CGGCCATGAAATCTTTTGAA-3‘ 5‘-AGACCATCGCCAATGAGTTC-3‘
HYOU-1 5‘-CTGCTCATTGAAAAGCCCA-3‘ 5‘-CTGCAGATCCGGGGAGTAG-3‘
doi:10.1371/journal.pone.0092041.t001
Figure 1. HSC70 (HSPA8) is the most prominent HSP70 isoform in MCC cell lines. D2CT levels of the known HSP70 isoforms were
determined applying SybrGreen real time PCR (red: MCPyV-positive; blue: MCPyV-negative; black: controls).
doi:10.1371/journal.pone.0092041.g001
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Results
HSC70 is the most prominent HSP70 isoform in MCC cell
lines
Since HSP70s are frequently overexpressed in cancer cells, we
determined mRNA expression levels of all known human HSP70
genes (excluding pseudo genes) in seven MCC cell lines using
SybrGreen based quantitative PCR assays (Fig. 1). To this end, the
mean expression of the isoforms HSPA1B, HSPA4, HSPA14,
APG1, STCH and HYOU-1 was low (high D2CT), although
expression varied widely among the different cell lines, in
particular for HSPA2. For all other HSP70 isoforms, mRNA
expression levels were high, i.e. equal to or above the mRNA
expression of the housekeeping gene GAPDH. Notably, HSC70
was the most abundantly expressed mRNA in all MCC cell lines
(low D2CT) and relative HSC70 transcript levels in the MCC cells
were higher than those in all non-transformed control cells
(HaCat, primary keratinocytes, primary fibroblasts). To confirm
that HSC70 mRNA levels correlated with protein expression, we
performed immunohistochemistry with cells of the respective
MCC cell lines embedded in a bovine plasma/thrombin clot prior
to formalin fixation. This analysis revealed a strong staining for
HSC70 in the cell lines WaGa and MCC13 (relative mRNA
expression compared to primary fibroblasts, the cell line with the
lowest expression: 22.6 and 64.0, respectively, data not shown);
however, under the same staining conditions, HSC70 was hardly
detectable in the BroLi and MKL-1 cell lines (relative mRNA
expression: 4.0 and 3.5, respectively, data not shown) (Fig. 2A).
Moreover, we stained patient derived tumor tissues for HSC70
expression, demonstrating its presence in MCC cells in situ as well
(Fig. 2B).
Figure 2. HSC70 protein expression in vitro and in vivo. HSC70 expression was assayed by immunohistochemistry applied to MCC cell lines
embedded in a bovine plasma/thrombin clot prior to formalin fixation (A) and FFPE MCC metastasis of a patient (B). The depicted scale bar measures
20 mm.
doi:10.1371/journal.pone.0092041.g002
Figure 3. Heterogeneous MAL3-101 sensitivity of MCPyV-positive and MCPyV-negative tumor cell lines. Cell lines were seeded with
10000 cells in 96-well plates and incubated for 24 h before they were treated for 72 h with the indicated concentrations of MAL3-101. Cell viability
was determined by the trypan blue exclusion assay (A, B). Given are mean values (+/- SD) of three independent experiments. FM88 is a melanoma cell
line, Jurkat cells are derived from a T-cell leukemia, while all other cell lines have been established from primary or metastatic MCCs. The MCPyV
status was determined by real time PCR and by immunohistochemistry for the MCPyV Large T antigen. MCPyV-positive cell lines are grouped in A and
C, and MCPyV-negative in B and D. The dashed line indicates an arbitrary threshold (80% viability) allowing the discrimination between MAL3-101
sensitive and resistant cell lines.
doi:10.1371/journal.pone.0092041.g003
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The HSP70 inhibitor MAL3-101 induces apoptosis in MCC
cell lines irrespective of their viral status
HSC70 is required for SV40-mediated cellular transformation
through its interaction with the LTA [42]. Therefore HSC70 or
other HSP70 isoforms may – in addition to other tumor-
promoting abilities – be of particular relevance for MCPyV
associated MCC by functioning with the MCPyV LTA. Conse-
quently, we studied the impact of the HSP70 inhibitor MAL3-101
on MCPyV-positive (Fig. 3A) and MCPyV-negative tumor cell
lines (Fig. 3B). The MCPyV-positive cohort included four MCC
cell lines that all strictly require MCPyV LTA expression for
maintenance. The MCPyV-negative cell lines investigated includ-
ed three putative MCC cell lines, one melanoma cell line (FM88),
and one T cell leukemia cell line (Jurkat). In either group, some
cell lines responded very sensitively to MAL3-101 and demon-
strated loss of viability, whereas others were hardly affected by the
inhibitor (Fig. 3). These observations indicate that the presence of
the polyoma virus is not critical for sensitivity towards MAL3-101,
a notion that is in agreement with the effect of MAL3-101 in small
cell lung cancer and myeloma [24,25]. Nevertheless, five out of
seven (72%) MCC cell lines responded to MAL3-101, suggesting
that MCC can be targeted by HSC70 inhibition. The Annexin-V
assay revealed a phosphatidylserine translocation in a large
proportion of sensitive cells after treatment, and DNA degradation
was evident (Fig. 4A and B). These data suggest that cell death
induced by MAL3-101 is via an apoptotic pathway.
Figure 4. MAL3-101 induces apoptosis in cell lines with high HSC70 expression. (A) DNA staining of MAL3-101 treated WaGa cells (relative
HSC70 mRNA level compared to primary fibroblasts: 22.6) reveals a strong increase in the sub-G1 population upon 20 h MAL3-101 treatment. In
contrast, treatment of MKL-1 cells (relative HSC70 mRNA level compared to primary fibroblasts: 3.5) did not result in induction of a sub-G1
population. (B) Annexin-V/7AAD staining demonstrates increased early apoptosis (quadrant 3) as well as increased cell death (quadrant 4) in WaGa
cells caused by MAL3-101 treatment (17 mM).
doi:10.1371/journal.pone.0092041.g004
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Significant correlation of MAL3-101 sensitivity with
HSC70 expression
Since the apoptotic response of tumor cells to MAL3-101 was
not dependent on the presence of MCPyV, we tested whether
MAL3-101 sensitivity would correlate with the level of HSP70
expression. Indeed, the viability of the treated MCC cell lines
displayed a significant correlation with HSC70 mRNA expression
(p = 0.0433, Spearman R=20.7029) (Figure 5).
MAL3-101 induces apoptosis in vivo and inhibits tumor
growth
To test whether MAL3-101 can affect MCC in vivo, we used a
recently established xenotransplantation model [12]. Following
subcutaneous injection of WaGa cells in NOD/Scid mice, animals
were treated with the inhibitor once palpable tumors reached a
size of approximately 100 mm3. Animals receiving 10 doses of
40 mg/kg MAL3-101 systemically over 21 days showed signifi-
cantly reduced tumor growth compared to the vehicle control
group (Fig. 6A and B). Tumor tissue was stained for cleaved
caspase III, revealing that the MAL3-101 treated tumors showed a
significantly higher presence of the cleaved form of caspase III
compared to the control group. Thus, MAL3-101 also induces
apoptosis in sensitive MCC cells in vivo (Figure 6C). Moreover, we
could not detect any abnormalities or limitations in the animal
behaviour or toxic side effects by MAL3-101 treatment suggesting
that systemic delivery of MAL3-101 was well tolerated.
Discussion
The five-year overall survival rate for patients with MCC is 40%
and the relative survival rate (compared to an age- and sex-
matched population) is 54% [39]. High mortality is largely due to
the high propensity even of small primary MCCs to metastasize,
and the resulting metastatic disease is treated by various
combinations of chemotherapeutics [43]. However, although good
initial response rates are achievable, the duration of these
responses is generally short and it has not been conclusively
demonstrated that any measure improves overall survival; thus,
the median survival is less than a year [6,11]. Therefore, there is a
great medical need for alternative therapeutic approaches to treat
MCC.
The discovery of a virus as a likely molecular cause for most
MCCs will facilitate the rational design of targeted therapeutics.
MCPyV was first described in 2008, followed by identification of
the viral oncogenes, i.e. the early genes or T antigens, and the
demonstration of an oncogene addiction of most MCPyV-positive
Figure 5. MAL3-101 sensitivity of MCC cell lines correlates with
HSC70 expression levels. The relative HSC70 mRNA expression
levels (with the lowest value arbitrarily set to 1) of the investigated cell
lines were blotted against viability following 72 h of treatment with
17 mM MAL3-101. Gaussian distribution of the data was confirmed by
using the Shapiro-Wilk normality test. Spearman’s correlation coefficient
as statistical test was applied.
doi:10.1371/journal.pone.0092041.g005
Figure 6. MAL3-101 treatment in an MCC xenotransplantation model demonstrated induction of apoptosis and reduced tumor
growth. WaGa cells embedded in MatriGel were injected s.c. in NOD.CB17-Prkdcscid/NCrHsd mice. Intraperitoneal injection of MAL3-101 (40 mg/kg)
was started (arrow) on day 17 when the tumor volume had reached approximately 100 mm3 and was repeated every second day. (A) Mean values (6
SEM, N=6) of the tumor volume are depicted in the graph. The p-value was calculated using the 2-way ANOVA statistical test. (B) Representative
macroscopic photographs depict the respective tumors at day 38. (C) IHC for cleaved caspase III in FFPE tumors excised on day 38 indicating caspase
III dependent apoptosis induction in the MAL3-101 treated group compared to control group. The depicted scale bar measures 20 mm.
doi:10.1371/journal.pone.0092041.g006
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MCC cell lines to these early genes [13]. Based on this notion and
on the assumption that in analogy to the SV40 encoded LTA,
MCPyV LTA may also critically depend on the HSP70 activity for
interference of Rb-E2F interactions, we wanted to test if HSP70
inhibition would be detrimental for MCPyV-positive MCC cell
lines.
HSP70 family members have been suggested as possible targets
for therapy of different cancer entities apart from MCC [44–46]
based on the following observations: HSP70 proteins (i) are
overexpressed in cancer cells and/or are induced upon chemo-
therapy, (ii) possess several cytoprotective and anti-apoptotic
functions [47], and (iii) have been demonstrated to be essential
for cancer cell survival [19]. In the case of MCpyV-positive MCC,
the essential role of HSP70 in the inactivation of the tumor
suppressor protein Rb by polyoma LTA [48–50] suggests that
HSP70 may be particularly crucial for this cancer type.
Here, we demonstrate that treatment with MAL3-101, a specific
inhibitor of HSP70 proteins, induces apoptosis in sensitive MCC
cells. Indeed, five out of seven MCC cell lines responded to
MAL3-101 at low micromolar concentration. Although we cannot
unequivocally conclude that survival of the MCC cells is affected
by the compounds ability to inhibit HSP70, these results suggest
that HSP70 might be a suitable target for therapy of some MCCs
and in particular that MAL3-101 is a candidate for treatment of
MCC. This notion is further substantiated by the effects of MAL3-
101 in a preclinical mouse model for MCC. Specifically, we
discovered that MAL3-101 is well tolerated by the mice and leads
to significantly reduced growth of the xeno-transplanted MCC
tumors. However, not all MCC cell lines were sensitive to the
HSP70 inhibitor; conspicuously, the variable response of MCC
cell lines to MAL3-101 did not correlate with the virus status of
these cells; i.e. both MCPyV-positive and -negative MCC cell lines
may be sensitive or resistant to MAL3-101. Instead, the sensitivity
of the MCC cell lines towards HSP70 inhibitor appears to
correlate with the expression level of HSC70 suggesting that a high
expression of this protein results in increased sensitivity to HSP70
inhibition.
The observation that one of the MCPyV-positive MCC cell
lines (BroLi) is almost completely insensitive to MAL3-101 may be
due to MCPyV LT - at least in this cell line - lacking HSP70
dependency as we have previously demonstrated that this cell line
is sensitive to MCPyV T antigen knock down [13]. Until recently,
it has only been shown that MCPyV LT binds HSC70 and that an
intact HSC70 binding site – which is present in MCPyV sT and
LT – is required for T antigen driven viral replication [14].
Whether HSC70 activity is necessary for the ability of MCPyV to
inactivate Rb and to support growth of MCPyV-positive MCC
cells has not yet been demonstrated. It is worth noting that select
functional differences between the MCPyV T antigens and their
SV40 homologs have been noted [51–53].
It was recently suggested that all MCCs are MCPyV associated
[54], putting into question whether the MCPyV-negative cell lines
that were all established before the identification of MCPyV are
really MCC cells. Indeed, these cells lack expression of many of the
MCC markers, in particular of cytokeratin-20 [13]. However, the
strongest response towards MAL3-101 among the MCC derived
cell lines is observed in two of the virus-positive cell lines.
Therefore, irrespective of the question of the identity of the
MCPyV-negative MCC derived cell lines, our data suggest that
inhibition of HSP70 by small molecule inhibitors such as MAL3-
101 may represent a novel therapeutic strategy for the treatment of
MCC either alone or in combination with other emerging
therapeutic options [11,55,56].
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